Early Intravenous Beta-Blockade with Esmolol in Adults with Severe Traumatic Brain Injury: A Phase 2a Intervention Design Study.

Matt ThomasKati HayesPaul WhiteThomas BaumerClodagh BeattieAravind RameshLucy CullifordGareth L AcklandAnthony E Pickering

Published in: Neurocritical care (2024)

Esmolol administration, titrated to a heart rate reduction of 15%, is feasible within 24 h of severe traumatic brain injury. The probability of dose-limiting toxicity requiring withdrawal of esmolol when using the optimized schedule is low. Trial registrationI SRCTN, ISRCTN11038397, registered retrospectively January 7, 2021 ( https://www.isrctn.com/ISRCTN11038397 ).

Keyphrases

clinical trial
severe traumatic brain injury
heart rate
traumatic brain injury
phase iii
heart rate variability
blood pressure
study protocol
randomized controlled trial
high dose
low dose